Título : |
Methodology for anti-gene anti-IGF-I therapy of malignant tumours |
Tipo de documento : |
documento electrónico |
Autores : |
Beatriz Helena Aristizábal Bernal, |
Fecha de publicación : |
2012 |
Títulos uniformes : |
Chemotherapy Research and Practice
|
Idioma : |
Inglés (eng) |
Resumen : |
The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+ and CD8+28+ molecules and a switch from CD8+11b+ to CD8+11. All cancer patients were supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL cells (CD8+ increased level). |
Mención de responsabilidad : |
Jerzy Trojan, Yuexin X. Pan, Ming X. Wei, Adama Ly, Alexander Shevelev, Maciej Bierwagen, Marie-Yvonne Ardourel, Ladislas A. Trojan, Alvaro Alvarez, Christian Andres, Maria C. Noguera, Ignacio Briceno, Beatriz H. Aristizabal, Heliodor Kasprzak, Huynh T. Duc, and Donald D. Anthony |
Referencia : |
Chemother Res Pract. 2012;2012:721873. |
DOI (Digital Object Identifier) : |
10.1155/2012/721873 |
PMID : |
22400112 |
Derechos de uso : |
CC BY |
En línea : |
https://www.hindawi.com/journals/cherp/2012/721873/ |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4917 |
Methodology for anti-gene anti-IGF-I therapy of malignant tumours [documento electrónico] / Beatriz Helena Aristizábal Bernal, . - 2012. Obra : Chemotherapy Research and PracticeIdioma : Inglés ( eng) Resumen : |
The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+ and CD8+28+ molecules and a switch from CD8+11b+ to CD8+11. All cancer patients were supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL cells (CD8+ increased level). |
Mención de responsabilidad : |
Jerzy Trojan, Yuexin X. Pan, Ming X. Wei, Adama Ly, Alexander Shevelev, Maciej Bierwagen, Marie-Yvonne Ardourel, Ladislas A. Trojan, Alvaro Alvarez, Christian Andres, Maria C. Noguera, Ignacio Briceno, Beatriz H. Aristizabal, Heliodor Kasprzak, Huynh T. Duc, and Donald D. Anthony |
Referencia : |
Chemother Res Pract. 2012;2012:721873. |
DOI (Digital Object Identifier) : |
10.1155/2012/721873 |
PMID : |
22400112 |
Derechos de uso : |
CC BY |
En línea : |
https://www.hindawi.com/journals/cherp/2012/721873/ |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4917 |
| |